Literature DB >> 7548906

Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis.

Y Inoue1, K Nishimura, M Shiode, H Akutsu, H Hamada, S Fujioka, S Fujino, A Yokoyama, N Kohno, K Hiwada.   

Abstract

SETTING: KL-6, a human MUC-1 mucin preferentially expressed on type II pneumocytes, is a sensitive serum marker for evaluating alveolar damage of interstitial pneumonia and pulmonary fibrosis. Some patients with pulmonary tuberculosis develop severe respiratory dysfunction caused by extensive pulmonary fibrosis, compensatory emphysema and fibrous pleural thickening.
OBJECTIVE: To evaluate the clinico-pathological significance of KL-6 in pulmonary tuberculosis.
DESIGN: Serum KL-6 levels were measured in sera from 57 patients with active pulmonary tuberculosis and 38 healthy controls by a sandwich-type enzyme-linked immunosorbent assay. Immunohistochemistry was performed by an avidin-biotin-peroxidase complex method.
RESULTS: KL-6 levels were significantly higher in the patients than in the healthy controls (518 +/- 693 [SD] vs 227 +/- 91 U/ml, P < 0.001) and increased significantly according to the extent of pulmonary lesions evaluated by chest X-ray (P < 0.001). There was a significant negative correlation between serum KL-6 levels and % vital capacity (VC) (r = 0.642, P < 0.05). KL-6 was strongly expressed on proliferated type II pneumocytes and cuboidal epithelial cells adjacent to thickened intralobular septa and pleura.
CONCLUSIONS: In pulmonary tuberculosis, serum KL-6 originates from proliferated type II pneumocytes and cuboidal epithelial cells, and is a useful marker presenting the degree and extent of pulmonary fibroproductive lesions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548906     DOI: 10.1016/s0962-8479(05)80010-3

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  13 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

2.  Use of an electronic nose to diagnose Mycobacterium bovis infection in badgers and cattle.

Authors:  R Fend; R Geddes; S Lesellier; H-M Vordermeier; L A L Corner; E Gormley; E Costello; R G Hewinson; D J Marlin; A C Woodman; M A Chambers
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy.

Authors:  Yosuke Matsuno; Hiroaki Satoh; Hiroichi Ishikawa; Takahide Kodama; Morio Ohtsuka; Kiyohisa Sekizawa
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Early control of Mycobacterium tuberculosis infection requires il12rb1 expression by rag1-dependent lineages.

Authors:  Halli E Miller; Richard T Robinson
Journal:  Infect Immun       Date:  2012-08-20       Impact factor: 3.441

Review 5.  Clinical use of biomarkers of survival in pulmonary fibrosis.

Authors:  Michiel Thomeer; Jan C Grutters; Wim A Wuyts; Stijn Willems; Maurits G Demedts
Journal:  Respir Res       Date:  2010-06-28

6.  Increased synthesis of anti-tuberculous glycolipid immunoglobulin G (IgG) and IgA with cavity formation in patients with pulmonary tuberculosis.

Authors:  Masako Mizusawa; Mizuoho Kawamura; Mikio Takamori; Tetsuya Kashiyama; Akira Fujita; Motoki Usuzawa; Hiroki Saitoh; Yugo Ashino; Ikuya Yano; Toshio Hattori
Journal:  Clin Vaccine Immunol       Date:  2008-01-09

7.  Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis.

Authors:  J F Djoba Siawaya; N Beyers; P van Helden; G Walzl
Journal:  Clin Exp Immunol       Date:  2009-01-22       Impact factor: 4.330

8.  Sequential changes of serum KL-6 predict the progression of interstitial lung disease.

Authors:  Ying Jiang; Qun Luo; Qian Han; Junting Huang; Yonger Ou; Miao Chen; Yu Wen; Silas Sethiel Mosha; Kuimiao Deng; Rongchang Chen
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 9.  Serum biomarkers in interstitial lung diseases.

Authors:  Argyris Tzouvelekis; George Kouliatsis; Stavros Anevlavis; Demosthenes Bouros
Journal:  Respir Res       Date:  2005-07-21

10.  Incidence and etiology of chronic pulmonary infections in patients with idiopathic pulmonary fibrosis.

Authors:  Kyuto Odashima; Naho Kagiyama; Tetsu Kanauchi; Takashi Ishiguro; Noboru Takayanagi
Journal:  PLoS One       Date:  2020-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.